VX-445/TEZ/IVA

DRUG2 trials

Sponsors

Vertex Pharmaceuticals Incorporated

Conditions

Cystic Fibrosis

Phase 3

A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)

CompletedNCT03525444

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2018-06-15End: 2019-04-24Updated: 2020-05-19

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

CompletedNCT03525548

Vertex Pharmaceuticals IncorporatedCystic Fibrosis

Start: 2018-08-03End: 2018-12-28Updated: 2020-01-27

Related Papers

S66 Impact of elexacaftor/tezacaftor/ivacaftor triple combination therapy on health-related quality of life in people with cystic fibrosis homozygous for F508del (F/F): results from a Phase 3 clinical study

2021-01-21

S65 Impact of elexacaftor/tezacaftor/ivacaftor triple combination therapy on health-related quality of life in people with cystic fibrosis heterozygous for F508del and a minimal function mutation (F/MF): results from a Phase 3 clinical study

2021-01-21

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

New England Journal of Medicine2019-10-311995 citations

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.

2019-10-31957 citations